Form 4: Reviva Pharma CEO Awarded 150K Stock Options

Reviva Pharmaceuticals Holdings, Inc. CEO Laxminarayan Bhat received new stock option awards totaling 150,075 shares with an exercise price of $1.87.

Summary

• Laxminarayan Bhat, President and CEO, Director, and 10% Owner of Reviva Pharmaceuticals Holdings, Inc. (RVPH), was granted stock options.
• The options were awarded on March 18, 2026, under the Issuer's 2020 Equity Incentive Plan.
• A total of 109,150 options were granted directly to Mr. Bhat, and an additional 40,925 options were granted indirectly through his spouse.
• The exercise price for all options is $1.87 per share, based on the closing price of the common stock on the grant date.
• For the direct grant, 34,110 shares vested immediately on the grant date, with the remaining 75,040 shares vesting in equal monthly installments from April 2026 to December 2028.
• For the indirect grant, 12,789 shares vested immediately, and 28,136 shares will vest in equal monthly installments from April 2026 to December 2028.
• All granted options have an expiration date of March 17, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating management's continued commitment and alignment with long-term shareholder value through equity incentives.

Positives

• The award of stock options aligns the interests of the President and CEO with those of shareholders, incentivizing long-term company performance.
• A significant portion of the options vests over several years, promoting executive retention and sustained focus on future growth.

Future Outlook

The vesting schedule extending to December 2028 implies a long-term commitment from the CEO, aligning his financial incentives with the company's sustained performance and growth over the coming years.

Industry Context

StockSavvy.ai notes that executive stock option awards are a common practice to align management interests with long-term shareholder value, particularly in the biotech/pharma sector where long development cycles and regulatory milestones are common drivers of value creation.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of these option awards, with immediate vesting for a portion and monthly vesting over several years for the remainder, is a standard practice in executive compensation plans across the pharmaceutical industry. This approach balances immediate reward with long-term retention and performance incentives.
• The exercise price being set at the closing price on the grant date is a typical method for granting 'at-the-money' options, common in equity incentive plans to ensure future value is tied to stock appreciation.

Corporate Governance

Related Party Transactions

• An indirect grant of 40,925 stock options to Laxminarayan Bhat through his spouse is reported, which is a standard disclosure for beneficial ownership.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term stock performance.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and compensation strategies.

Next Steps

• Continued vesting of 75,040 directly held options in equal monthly installments from April 2026 to December 2028.
• Continued vesting of 28,136 indirectly held options in equal monthly installments from April 2026 to December 2028.

Key Dates

Keywords

RVPH, Reviva Pharmaceuticals, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Incentive Plan, Laxminarayan Bhat